Education
About Us
Working with TipRanks
Follow Us
Sanjay Chanda Insider Profile
11 Followers
Sanjay Chanda, SVP, Drug Development at Anacor Pharmaceuticals, holds 118.82K shares in AN2 Therapeutics, Inc. (Ticker: ANTX), holds 29.09K shares in Anacor Pharmaceuticals (Ticker: ~ANAC).
Sanjay Chanda Anacor Pharmaceuticals (~ANAC)SVP, Drug Development
Anacor Pharmaceuticals (~ANAC)
SVP, Drug Development
Not Ranked
Sanjay Chanda has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CDO
Roles that Sanjay Chanda holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Sanjay Chanda
Sanjay Chanda's Trading History
Anacor Pharmaceuticals
Mar 04, 2015
―
Uninformative Sell
225.00K
$2.88M
AN2 Therapeutics, Inc.
Feb 23, 2026
CDO
Uninformative Buy
―
$623.82K
List of latest transactions for each holding click on a transaction to see Sanjay Chanda's performance on stock
You May Also Like
Sanjay Chanda insider profile FAQ
What is the percentage of profitable transactions made by Sanjay Chanda?
The percentage of profitable transactions made by Sanjay Chanda is ―.
What is the average return per transaction made by Sanjay Chanda?
The average return per transaction made by Sanjay Chanda is ―.
What stocks does Sanjay Chanda hold?
Sanjay Chanda holds: ~ANAC, ANTX stocks.
What was Sanjay Chanda’s latest transaction?
Sanjay Chanda latest transaction was an Uninformative Buy of ―.
What was Sanjay Chanda's most profitable transaction?
Sanjay Chanda’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Sanjay Chanda's role in Anacor Pharmaceuticals?
Sanjay Chanda's role in Anacor Pharmaceuticals is SVP, Drug Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.